Drug Details

General Information of the Drug (ID: DR4175)
Name
Domperidone
Synonyms
domperidone; 57808-66-9; Motilium; Nauzelin; Domperidonum; Domperidona; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; R-33812; R 33,812; NSC299589; Domperidone (Motilium); 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone; R33812; UNII-5587267Z69; KW 5338; MLS000069343; CHEMBL219916; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; CHEBI:31515; MFCD00069256; 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one; NSC 299589; NSC-299589; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; Motinorm; Costi; 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone; DSSTox_CID_25116; DSSTox_RID_80682; DSSTox_GSID_45116; 1-(3-(4-(5-chloro-2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[d]imidazol-2(3H)-one; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 5-Chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one; Domperidonum [INN-Latin]; Domperidona [INN-Spanish]; 5587267Z69; Motillium; Motilium (TN); SMR000326802; CAS-57808-66-9; KW-5338; Lopac-D-122; SR-01000003002; EINECS 260-968-7; BRN 0903774; Nauzelin OD; Domperidone,(S); 5-chloro-1-{1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one; Domperidone [USAN:INN:BAN:JAN]; Prestwick_794; NCI299589; HS-0067; PubChem15679; Spectrum_000391; Opera_ID_616; SpecPlus_000825; Prestwick0_000461; Prestwick1_000461; Prestwick2_000461; Prestwick3_000461; Spectrum4_000087; D-122; Biomol-NT_000022; NCIStruc1_001686; NCIStruc2_001819; Lopac0_000427; SCHEMBL43729; BSPBio_002350; GTPL965; KBioGR_000354; KBioSS_000871; 2H-Benzimidazol-2-one, 5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-; 5-24-02-00402 (Beilstein Handbook Reference); MLS000859942; MLS001306482; MLS002222324; DivK1c_006921; SPECTRUM2300212; SPBio_002501; BPBio1_000620; BPBio1_001185; DTXSID1045116; Domperidone (JP17/USAN/INN); KBio1_001865; KBio2_000871; KBio2_003439; KBio2_006007; HMS1922N04; HMS2089C14; HMS2093N22; HMS2096C21; HMS2230N18; HMS3261E16; HMS3269O13; HMS3370L03; HMS3413F15; HMS3656M21; HMS3677F15; HMS3713C21; HMS3884N19; Pharmakon1600-02300212; BCP28265; Domperidone 1.0 mg/ml in Methanol; EBD46624; HY-B0411; ZINC4175569; Tox21_110056; Tox21_500427; ANW-42358; BBL028136; BDBM50241107; CCG-37870; CD0227; NCGC00014670; NSC759575; s2461; STK622843; AKOS005555858; Tox21_110056_1; AC-2037; DB01184; Domperidone, powder, >=98% (HPLC); LP00427; MCULE-4430288884; NSC 759575; NSC-759575; SDCCGSBI-0050412.P004; NCGC00014670-01; NCGC00014670-02; NCGC00014670-03; NCGC00014670-04; NCGC00014670-05; NCGC00014670-06; NCGC00014670-07; NCGC00014670-08; NCGC00014670-09; NCGC00014670-10; NCGC00014670-11; NCGC00014670-12; NCGC00014670-13; NCGC00014670-14; NCGC00014670-16; NCGC00014670-17; NCGC00014670-28; NCGC00015306-01; NCGC00021472-02; NCGC00021472-03; NCGC00021472-04; NCGC00021472-05; NCGC00021472-06; NCGC00021472-07; NCGC00021472-08; NCGC00097773-01; NCGC00261112-01; 2H-Benzimidazol-2-one, 1,3-dihydro-5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one; NCI60_002512; SMR000058969; AB0110085; AB00052423; D4125; EU-0100427; FT-0625588; SW196931-3; D01745; AB00052423-06; AB00052423-07; AB00052423_08; AB00052423_09; 808D669; L000230; Q424238; R 33812; SR-01000003002-2; SR-01000003002-4; SR-01000003002-7; W-105440; BRD-K38305202-001-02-6; BRD-K38305202-001-08-3; Domperidone, European Pharmacopoeia (EP) Reference Standard; 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolyl)propyl]-4-piperidyl]benzimidazol-2-one; 2H-Benzimidazol-2-one,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo -1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-d ihydro-2H-benzimidazol-2-one; 5-Chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1- yl)propyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidine-4-yl]-1,3-dihydro-2H-benzimidazol-2-one;; 5-chloro-1-{1-[3(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-{1-[3-(1,3-dihydro-2-oxo-2H-benzimidazol-1-yl)propyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one; 5-Chloro-1-{1-[3-(2-hydroxy-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-2,3-dihydro-1H-benzoimidazol-2-ol; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 5-Chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one(domperidone); DOMPERIDONE5-Chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one
    Click to Show/Hide
Molecular Type
Small molecule
Disease Digestive system disease [ICD-11: DE2Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability
Clearance
The drug present in the plasma can be removed from the body at the rate of 9.5 mL/min/kg
Elimination
0% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 7 hours
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3354 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.082%
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.4 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 0.006 mg/mL
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C22H24ClN5O2
PubChem CID
3151
Canonical SMILES
C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O
InChI
1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
InChIKey
FGXWKSZFVQUSTL-UHFFFAOYSA-N
CAS Number
CAS 57808-66-9
ChEBI ID
CHEBI:31515
TTD Drug ID
D0AV3G
DrugBank ID
DB01184
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Pseudoephedrine      Ephedra altissima     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 The combination of domperidone and pseudoephedrine improved self reported snoring and sleepiness, and may have improved apneic episodes and sleep-related nocturnal oxygen desaturation in patients with obstructive sleep apnea provided the proportion of time spent asleep did not diminish.
Target and Pathway
Target(s) Dopamine D2 receptor (D2R)  Molecule Info  [3]
KEGG Pathway Rap1 signaling pathway Click to Show/Hide
2 cAMP signaling pathway
3 Neuroactive ligand-receptor interaction
4 Gap junction
5 Dopaminergic synapse
6 Parkinson's disease
7 Cocaine addiction
8 Alcoholism
Panther Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway Click to Show/Hide
2 Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
3 Dopamine receptor mediated signaling pathway
4 Nicotine pharmacodynamics pathway
Reactome Dopamine receptors Click to Show/Hide
2 G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction Click to Show/Hide
2 Monoamine GPCRs
3 GPCRs, Class A Rhodopsin-like
4 Genes and (Common) Pathways Underlying Drug Addiction
5 GPCR ligand binding
6 GPCR downstream signaling
7 Nicotine Activity on Dopaminergic Neurons
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 965).
Reference 2 Pharmacological treatment of obstructive sleep apnea with a combination of pseudoephedrine and domperidone. J Clin Sleep Med. 2010 Apr 15;6(2):117-23.
Reference 3 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
 Download Picture         KEGG Link